Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Pharmatek Increases Liquid-Filling Capacity

By Drug Discovery Trends Editor | April 18, 2012

Pharmatek Laboratories Inc., a contract development and manufacturing organization (CDMO) supporting the pharmaceutical industry, announced that it has expanded its existing liquid encapsulation capabilities by purchasing a Qualicaps FS3 automated liquid filling and banding system. The addition of the Qualicaps FS3 unit to Pharmatek’s manufacturing capabilities increases overall efficiency at the Phase 2 production scale.

“The Qualicaps FS3 unit increases our scale of capsule filling, and it also has a number of other features that increase the quality of this particular dosage form,” stated Kevin Rosenthal, Director of Manufacturing for Pharmatek. “It has a robust gelatin band sealing technology that allows a quick visual check of seal integrity. The Qualicaps FS3 unit also has a heated hopper system for handling a broad range of liquid viscosities, including semi-solid and other BCS Class II formulations.”

The Qualicaps FS3 unit is equipped with an inert gas purge system and unique capsule lifting feature, allowing for the handling of oxygen sensitive drug products. The inert gas purge system presents warmed air, or inert gas, into the headspace of the capsule, minimizing process defects and thus increasing the overall product yield. The FS3 liquid filling and banding system is configured to handle clear or colored banding and gelatin or HPMC capsules ranging in sizes from 4 to 00.

“The acquisition of the Qualicaps FS3 unit increases our cGMP liquid capsule filling rate substantially. This increased rate allows Pharmatek to be more cost effective for larger scale liquid encapsulation projects. More efficient production of larger scale batches helps us to better support our clients through their late-stage Phase 2b clinical studies,” stated Jeffrey Bibbs, CEO and CSO of Pharmatek.

Date: April 16, 2012
Source: Pharmatek Laboratories Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE